M-A | Avaliação do risco de eventos cardiovasculares por uso de tirzepatida.
19 Mai, 2022 | 12:41hTirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Comentário: Meta-analysis backs tirzepatide CV safety – medwireNews
Comentário no Twitter
A meta-analysis of cardiovascular secondary outcomes from the SURPASS program, testing efficacy of a new novel dual GIP/GLP-1 receptor agonist tirzepatide, demonstrates cardiovascular safety in patients with type 2 #diabetes https://t.co/xQBbj3Egkg
— Nature Medicine (@NatureMedicine) February 25, 2022